Abbott to Pay $385 Million to Settle Baby Formula Plant Claims
Abbott Laboratories agreed to pay $385 million to resolve claims related to contamination at its Sturgis, Michigan plant, which caused a 2022 recall and shortages. The settlement does not constitute an admission of fault. The Justice Department has closed its criminal investigation into the matter.
The settlement resolves claims brought by the Justice Department, state attorneys general, and whistleblower relators, though Abbott maintains the payment does not constitute an admission of wrongdoing. The company has consistently pointed to negative test results on unopened products from homes of affected infants during the 2022 investigation.
The Sturgis facility closure created a cascading crisis in the infant formula market, compounding existing supply chain pressures from the pandemic era. Federal authorities responded with emergency measures including relaxed import rules and airlifts of formula from Europe. The plant resumed operations within roughly four months of its February 2022 shutdown.
This settlement could affect public trust in infant formula manufacturers and regulatory oversight. Families relying on formula products may scrutinize safety practices more closely, while the resolution may influence how similar contamination cases are handled in the future. The closure's ripple effects on supply chains could prompt policymakers to consider more resilient production strategies, though the long-term impact on consumer confidence remains uncertain.